Abstract: Many human genetic disorders result from unbalanced chromosome abnormalities, in which there is a net gain or loss of genetic material. Such imbalances often disrupt large numbers of dosage-sensitive, developmentally important genes and result in specific and complex phenotypes. Alternately, some chromosomal syndromes may be caused by a deletion or duplication of a single gene with pleiotropic effects. Traditionally, chromosome abnormalities were identified by visual inspection of the chromosomes under a microscope. The use of molecular cytogenetic technologies, such as fluorescence in situ hybridization and microarrays, has allowed for the identification of cryptic or submicroscopic imbalances, which are not visible under the light microscope. Microarrays have allowed for the identification of numerous new syndromes through a genotype-first approach in which patients with the same or overlapping genomic alterations are identified and then the phenotypes are described. Because many chromosomal alterations are large and encompass numerous genes, the ascertainment of individuals with overlapping deletions and varying clinical features may allow researchers to narrow the region in which to search for candidate genes.
Introduction
Humans have 23 pairs of chromosomes, ie, one pair of sex chromosomes (X and/or Y) and 22 pairs of autosomes (chromosomes . Many human genetic disorders result from unbalanced chromosome abnormalities, in which there is a net gain or loss of genetic material. Numeric and structural chromosomal abnormalities occur in approximately 0.6% of live births, 1 and often result in dysmorphism, malformations, and/or developmental disabilities. The resulting phenotypes are caused by the imbalance of one or more dosage-sensitive genes in a particular chromosome or chromosomal segment. Such gene imbalances often have devastating consequences and cause 25% of all miscarriages and stillbirths, and 50%-60% of first-trimester miscarriages.
individual. Certain trisomies, such as trisomy 8 and 9, rarely occur in all cells and are mostly found in individuals with mosaicism.
In contrast with numeric abnormalities, structural chromosomal abnormalities result from the breakage and subsequent reunion of chromosome arms. Some structural chromosome abnormalities result in gain or loss of material. Deletions involve the loss of a segment of a chromosome and duplications result in a gain of a chromosome segment. Deletions may be terminal or interstitial; a terminal deletion results after one break in the chromosome with loss of the segment distal to the break, whereas an interstitial deletion results after two breaks in the chromosome, with the loss of the intervening segment, and rejoining of the remaining chromosome segments. A duplication is caused by the gain of a copy of a chromosomal segment at the original location on the chromosome. Duplications may be in an inverted orientation or in the original (direct) orientation.
Other structural chromosome abnormalities do not result in gain or loss of any genetic material. Such rearrangements include inversions, which are caused by a twobreak event and the end-to-end reversal of the intervening chromosomal segment; translocations, which result from the exchange of chromosome segments between two or more chromosomes; and insertions, which occur when a segment of one chromosome is translocated and inserted into a new region of the same chromosome, the other homolog, or a nonhomologous chromosome. These rearrangements may be pathogenic if a gene(s) is disrupted by a rearrangement breakpoint, a novel fusion gene product is formed, or a position effect is exerted on genes neighboring the rearrangement.
Compared with, for example, single-gene mutations, chromosome abnormalities often disrupt large numbers of developmentally important genes. Such imbalances may alter the dosage of genes expressed within the affected chromosomal segment, resulting in clinical consequences for the individual (see Table 1 ). Some imbalances result in a contiguous gene syndrome, in which multiple genes within the deleted or duplicated region are affected, each contributing a discrete clinical feature to the phenotype. 3 Alternately, some chromosomal syndromes may be caused by a deletion or duplication of a single gene with pleiotropic effects. For most deletion syndromes, deletion causes haploinsufficiency of a gene or genes in the region, in which the remaining intact copy of the gene does not produce sufficient gene product for normal function. Haploinsufficiency for specific genes has been identified in several syndromes, including Williams syndrome, Langer-Giedion syndrome, Miller-Dieker syndrome, and DiGeorge/velocardiofacial syndrome.
Traditionally, chromosome abnormalities were identified by visual inspection of the chromosomes under a microscope. Each chromosome can be divided into bands, which are sections of a chromosome that can be distinguishable from adjacent sections by lighter or darker variations in intensity following one or more staining methods. The original reports of chromosome rearrangements were made prior to the development of these staining techniques. Thus, any rearrangements recognized under the microscope were either numeric or an altered segment of the chromosome large enough so that the affected homolog could be easily distinguished from the normal homolog based on the overall size of the chromosome. 4, 5 The development of banding techniques and high-resolution chromosome analysis enabled the detection of subtle rearrangements that affected one or a few chromosome bands. The use of molecular cytogenetic technologies, such as fluorescence in situ hybridization (FISH) and microarrays, has allowed for the identification of cryptic or submicroscopic imbalances, which are not visible under the light microscope ( Figure 1 ). Numerous previously unrecognized microdeletion and microduplication syndromes have been identified by these molecular cytogenetic techniques. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In 1986, Schmickel 3 first described contiguous gene syndromes (CGS) as involvement of multiple genes located in close proximity to each other on a chromosome. This term has been refined over the years and expanded to include a group of disorders defined by a deletion or duplication of a chromosomal segment spanning more than one disease gene, each affecting the phenotype independently. CGS have been described for many disorders mapping to various chromosomes. Disorders now recognized as CGS often have subtle cytogenetic changes that cannot always be resolved with conventional cytogenetic methods. Molecular cytogenetics, specifically FISH and microarray analysis, has helped to characterize many CGS.
Terminal rearrangements
Of all cytogenetically visible structural abnormalities, the majority occur in the distal telomeric bands of the chromosomes. 17 Telomeres are specialized protein-DNA structures at the ends of all linear chromosomes that play numerous important cellular roles, including the prevention of chromosome degradation and end-to-end chromosome fusions, 18 as well as the proper pairing, recombination, and segregation of chromosome homologs during meiosis. 20 Proximal to this telomeric repeat tract is a structurally complex region of subtelomeric DNA that can extend several hundred kb from the end of most chromosomes and has been shown to be highly polymorphic. [21] [22] [23] [24] Present on all but the short arms of acrocentric chromosomes 13-15 and 21-22, the unique subtelomeric regions have elicited study because they are relatively gene-rich 25, 26 and are prone to rearrangement by a number of mechanisms. 27, 28 Thus, rearrangements of the subtelomeric regions have been suggested to represent a high proportion of abnormalities in individuals with idiopathic mental retardation and, because they are gene-rich, to result in more significant clinical consequences than similarly sized imbalances elsewhere in the genome. 17, 25, 29 Several clinically well recognized genetic disorders are associated with terminal deletions, including deletion of distal 5p associated with cri du chat syndrome 4 and distal deletion of 4p associated with Wolf-Hirschhorn syndrome. 5, 30 Deletion of the distal band of the short arm of chromosome 1 (monosomy 1p36) is the most common terminal deletion syndrome, occurring in about 1 in 5000 newborns. [7] [8] [9] The development of sets of FISH probes for the simultaneous interrogation of all the unique human subtelomeres 29, 31, 32 has allowed for the detection of submicroscopic chromosomal abnormalities in patients with idiopathic mental retardation but without features suggestive of a particular syndrome. The largest study of subtelomeric abnormalities to date examined 11,688 cases with subtelomere FISH and detected pathogenic abnormalities in 2.6%. 33 Visible deletions of every telomeric band have been identified. 17 Some of these abnormalities have been identified in a sufficiently large number of patients that the abnormality can be conclusively linked to the phenotype, which could in turn be delineated by comparison of clinical features among affected individuals. 34, 35 Other subtelomeric abnormalities have been identified in only one or a few patients and cannot be considered syndromic until a consistent collection of clinical features is delineated.
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Because the distal G-negative bands of the unique chromosome arms are gene-rich, 25 deletion or retention of this region may have profound clinical consequences in individuals with telomeric imbalances. Thus, accurate delineation of the nature of the imbalance, either terminal or interstitial, is crucial for diagnosis and prognosis. Recent large-scale prospective studies using microarrays show interstitial deletions are two to three times more frequent than terminal imbalances. 36, 37 Recently, Ballif et al 38 characterized 169 cases with subtelomeric abnormalities identified by microarray analysis. Of these 169 cases, 42 had interstitial deletions. In addition, six (3.5%) individuals had complex rearrangements that showed deletions with duplications or additional deletions. The identification of complex rearrangements suggests chromosome abnormalities are often more complex than what was once thought.
Recurrent abnormalities mediated by underlying genomic architecture
Many recurrent chromosomal abnormalities are caused by nonallelic homologous recombination (NAHR) mediated by flanking segmental duplications. [39] [40] [41] [42] In NAHR, improper crossing-over between nonallelic, directly repeated, homologous segments (such as low-copy repeats) between sister chromatids (intrachromosomal) or between homologous chromosomes (interchromosomal) produces two reciprocal products, ie, a tandem or direct duplication and a deletion.
Such recurrent syndromes are termed "genomic disorders" and usually meet several criteria, ie, the rearrangement has breakpoints in flanking segmental duplications, the rearrangement is almost always de novo in affected individuals and is rarely seen in controls, and patients with the same 
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Theisen and Shaffer rearrangement have similar, consistent phenotypes. 40, 41 The underlying genomic architecture in each of the genomic disorders identified to date is similar, ie, a stretch of unique sequence (50 kb-10 Mb) flanked by large (.10 kb), highly homologous (.95%) segmental duplications that provide the substrate for NAHR.
NAHR has been implicated in the recurrent rearrangements in Charcot-Marie-Tooth disease, 43 hereditary neuropathy with liability to pressure palsies, 44 and Prader-Willi, 45 Angelman, 46 Smith-Magenis, 47 DiGeorge/velocardiofacial (DGS/VCFS), 48 Williams-Beurens, 49 and Sotos 50 syndromes (see Table 1 ). Almost invariably, the abnormalities identified in individuals with the same genomic disorder are of identical size. For example, the common deletion in 7q11.23 found in Williams syndrome is about 1.6 Mb in size 51 and is present in greater than 90% of patients. 52, 53 The common Smith-Magenis syndrome deletion within 17p11.2 is approximately 5 Mb 47, 54 and is found in the majority of patients. 47, 55 Approximately 90% of individuals with DGS/ VCFS have an approximately 3 Mb deletion at 22q11.2, and most of the remainder have an alternate distal deletion breakpoint, resulting in a smaller 1.5 Mb deletion, and both deletions are mediated by closely related low copy repeats in the region. 56 Atypical breakpoints have been reported for other recurrent rearrangements mediated by segmental duplications. For example, some of the rarer rearrangements of 17p11.2 associated with Smith-Magenis syndrome do not have breakpoints flanked by the typical paired segmental duplications, and are not associated with known genomic architectural features, 57 and some of the breakpoints in the recently identified 16p11.2p12.2 microdeletion syndrome are not flanked by segmental duplications. 16 Nonallelic homologous recombination predicts that reciprocal duplications of low copy repeat-mediated deletions should occur with equal frequency. 40 However, duplications have been reported more rarely than expected. [58] [59] [60] [61] [62] One explanation is that individuals with duplications usually have milder phenotypes that may not lead to clinical investigation than individuals with deletions. 59, [61] [62] [63] [64] [65] [66] Furthermore, duplications involving segments smaller than 1.5 Mb may be routinely missed, even by FISH of interphase nuclei. 67 However, recent large population studies of individuals tested by microarray analysis have shown that the frequency of reciprocal duplications is higher than in previous studies with other cytogenetic technologies. [68] [69] [70] [71] Duplications of the common Rett syndrome gene MECP2 have been identified in males with developmental delay, 72 and the reciprocal duplications of microdeletion syndromes, such as 3q29 microdeletion syndrome, 73 Williams-Beuren syndrome, 74 and the 22q11.21 microdeletion syndrome, 59 have been identified by microarray testing. The clinical significance of some of these reciprocal duplications is not known. For example, only two individuals had de novo microduplications of 3q29, whereas the remaining cases were inherited from a carrier parent. Thus, the clinical significance of these duplications is unclear, and any phenotype may be modulated by an as yet unidentified genetic modifier.
Several new syndromes, including 8p23 duplication 75 and 16p12.1 microdeletion, 76 can be transmitted from parent to child. The study of 16p12.1 microdeletions presents an interesting case study of the previously underappreciated complexity of genetic disorder pathogenesis. Recurrent microdeletions of 16p12.1 have been identified in individuals referred for genetic testing for idiopathic mental retardation and congenital anomalies, and appear to be enriched in such individuals compared with clinically normal controls. 76 Almost all the 16p12.1 microdeletions identified have been inherited from a carrier parent. Carrier parents for the 16p12.1 microdeletion are more likely to exhibit learning disability, bipolar disorder or depression, and seizures than noncarrier parents. The presence of varying degrees of learning disability in the adult family members suggests that some transmitted abnormalities are pathologic and have an underappreciated contribution to the phenotype.
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Deletions of varying size may elucidate causative genes for syndromes Because many chromosomal alterations are large and encompass numerous genes, the ascertainment of individuals with overlapping deletions and varying clinical features may allow researchers to narrow the region in which to search for candidate genes. For example, varying-sized deletions at Xp21 comprise a contiguous gene syndrome that encompasses seven disorders, ie, adrenal hypoplasia congenita, glycerol kinase, Duchenne muscular dystrophy, McLeod phenotype, chronic granulomatous disease, retinitis pigmentosa, and ornithine transcarbamylase deficiency. The first recognized patient with an Xp21 contiguous gene deletion was diagnosed with Duchenne muscular dystrophy associated with chronic granulomatous disease, retinitis pigmentosa, and McLeod phenotype. 77 Molecular studies of subsequent individuals with varyingsized deletions at Xp21 and varying phenotypes allowed for the construction of a disease gene map and the identification of causative genes for each of these disorders.
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Such an approach also allowed researchers to delineate the critical regions of trichorhinophalangeal syndrome type 1 and trichorhinophalangeal syndrome type 2, also known as Langer-Giedion syndrome. Langer-Giedion syndrome combines the features of trichorhinophalangeal syndrome type 1 and multiple exostoses type 1. The cytogenetic basis of Langer-Giedion syndrome was unknown until high-resolution banding identified interstitial deletions in the long arm of chromosome 8 in patients with this syndrome, 82, 83 and the location of the deletion was subsequently determined to be 8q24.1. 84, 85 Mapping of the deletion breakpoints in a cohort of Langer-Giedion syndrome patients showed that 75% have cytogenetically detectable deletions of 8q24.1. 86 The identification of an individual with trichorhinophalangeal syndrome Type 1 but not exostoses and with a partial microdeletion of 8q23 87 suggested that Langer-Giedion syndrome was caused by deletion of two or more genes, disruption of one of which results in trichorhinophalangeal syndrome Type 1 and disruption of the other of which results in multiple exostoses. Buhler et al 88 concluded that the Langer-Giedion syndrome is due to a deletion extending from 8q24.11 to 8q24.13, whereas trichorhinophalangeal syndrome Type 1 is caused by an even smaller deleted segment, namely, 8q24.12. Thus, it was determined that Langer-Giedion syndrome, which combines features of trichorhinophalangeal syndrome Type 1 and multiple exostoses, is a contiguous gene syndrome caused by haploinsufficiency of both TRPS1 and EXT1. 
Genotype-first approach to diagnosis
Many of the recently identified syndromes have been identified through a genotype-first approach, rather than a typical phenotype-first approach. 6 In the phenotype-first approach, the astute clinician would gather patients based on clinical presentation. This approach took many years to observe several rare individuals and develop a syndrome. The resulting syndromes had very consistent phenotypes among patients. In contrast, the genotype-first approach identifies patients with the same or overlapping genomic alterations and then describes the phenotypes observed. In this latter approach, the patients often display varying features, and in hindsight would not have been grouped based on clinical presentation alone.
Recently, microarrays designed to interrogate known segmental duplication "hotspots" of the genome have identified several previously unrecognized genomic disorders. 92 have been identified in such a manner. In all cases, the majority of patients identified met the classical definition of a recurrent genomic disorder. The deletions were flanked by segmental duplications, the deletions were always apparently de novo in origin, and the patients had similar clinical features. 41 However, the clinical features of these syndromes do not usually evoke a diagnostic Gestalt, which demonstrates the utility of the genotype-first approach in the absence of striking clinical features.
The genotype-first approach may also enable the identification of small deletions or duplications that reveal the causative genes for specific clinical features, which can aid diagnosis and prognosis. For example, researchers recently identified what is likely to be the causative gene for features of 2q32q33 microdeletion syndrome. 92 Individuals with the syndrome have severe mental retardation, growth retardation, dysmorphic facial features, thin and sparse hair, feeding difficulties, and cleft or high palate. Although deletions of varying sizes have been reported, the smallest region deleted in all patients contains at least seven genes. One of these genes, SATB2, is a DNA-binding protein that regulates how genes are expressed. Deletion of SATB2 has been suggested to cause the cleft or high palate of individuals with 2q32q33 microdeletion syndrome. The recent study identified three individuals with small deletions of this region, all of which spanned part of SATB2. Common clinical features among these individuals included severe developmental delay, behavioral problems, and tooth abnormalities. Interestingly, only one of the individuals had a cleft palate. Because the individuals had a portion of only one gene missing and the presence of many of the features associated with the larger microdeletion syndrome, the study authors suggested deletion of SATB2 was sufficient to cause several of the clinical features associated with 2q32q33 microdeletion syndrome.
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Summary
Chromosomal disorders are the most frequent cause of mental retardation and developmental disabilities in our population. The phenotypes are often complex, and the result of a gain or loss of multiple, dosage-sensitive genes in the altered segments. The characterization of these complex phenotypes with overlapping deletions has allowed for the identification of genes causing particular features of the syndrome. The use of high-resolution technologies, such as microarrays, has allowed for the identification of new syndromes through a genotype-first approach at an unprecedented frequency never before imagined through the light microscope. Cytogenetics is no longer in its infancy, and has emerged a "new" genome science that, with the use of new technologies, has established the causes of mental retardation, developmental disabilities, and birth defects in our population. 
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